Kronos Bio, Inc. announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Company?s pipeline, including the ongoing phase 1/2 study of KB-0742 following the review of additional positive preliminary safety and efficacy data. The company expects these efforts, which include a 21% reduction in force, will extend cash runway into the second half of 2026.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 USD | 0.00% | -0.97% | -18.40% |
05-09 | Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M | MT |
05-09 | Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.40% | 61.3M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+43.51% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- KRON Stock
- News Kronos Bio, Inc.
- Kronos Bio Plans to Reduction in Force